|Chief Executive Officer|
Tapas K. De, PhD
|Extensive industrial experience with both proteins/enzymes and small molecules in formulation and process development, including scale-up/technology transfer. Scientific specializations in parenteral and ocular drug delivery and release kinetics, nanoparticle (ceramic, polymeric, bioadhesive, hydrogel) formulation development, reverse micellar enzymology, enzyme kinetics and reaction mechanism. Expert on nab formulation development and characterization. Developed Abraxane nanoparticle formulation at Abraxis Bioscience, as well as nab-17-AAG, nab-docetaxael, nab-rapamycin, nab-ABI011 etc. Lead formulation scientist for the nab business venture with National and international pharmaceuticals companies.|
|VP of CMC|
Zachary Yim, PhD
|Highly creative, versatile and productive professional in formulation/drug delivery and product development of biologicals, such as recombinant proteins, monoclonal antibodies, vaccines and small molecules, encompassing all traditional oral and injectable dosages forms as well as novel delivery systems, such as sustained release depots, liposomes, nanoparticles, polymeric micelles and vaccines and drug-device combinations.
Abraxis Biosciences (ABI), Medarex, Curagen, Entremed, Repligen, Centocor, Cytogen, Schering-Plough, Roche
|Director of R&D - Electrochemistry|
Steven T. Miller
|Mr. Miller brings more than 25 years in pharmaceutical drug discovery research experience. He was an integral part of the discovery of the ocular anti-allergy utility of olopatadine (Patanol) and potential backups with related patents and publications. Currently, Mr. Miller is the Director of R&D – Electrochemistry working in the formulation lab in Fort Worth, Texas.
UT Southwestern, Alcon, Alcon/Novartis(NIBR)
narrative essay outline